| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2011 , Vol 53 , Num 3
FORMULATION AND EVALUATION OF PACLITAXEL NIOSOME FOR ITS IMPROVED ANTI-CANCER ACTIVITY
Department of Pharmaceutics, Periyar College of Pharmaceutical Sciences, Tiruchirappalli, Tamil Nadu, India
Viewed :
19264
-
Downloaded :
12470
The present work was to formulate Paclitaxel niosomes and evaluate for its in vitro cytotoxic studies using HEP-2 and HELA-human cancer cell lines. Drug-excipients interaction study revealed that there was no interaction between the drug and excipients. Formulations made with span 60 was the most satisfactory with the entrapment 97.0%; particle size 800-850 nm; the release was found to be 95.6% after 17 h and compared the LD50 with the standard formulation Taxol. Effects of volume of organic solvent, surfactant and cholesterol ratio were also studied. The stability study results revealed that the prepared formulation was stable in the stress condition.
Keywords :
PACLITAXEL, NIOSOME, CANCER CELL, HEP-2, HELA